5 Monivong Boulevard, P.O Box. 983, Phnom Penh, Cambodia [email protected]
    • 05 APR 16

    Séminaire sur “In vitro evaluation of novel antimalarial compounds in the context of P. falciparum multiresistance”, par Flore Nardela

    The Committee of Scientific Animation of Institut Pasteur du Cambodge ([email protected]org) will organise the following seminar:

    Seminar

    Free admission

    Thursday 7th of April 2016

    At 14h00 in Administration room of Institut Pasteur du Cambodge, 1st floor

    In vitro evaluation of novel antimalarial compounds in the context of P. falciparum multiresistance

    by Flore Nardela

    Institut Pasteur du Cambodge

     

    SUMMARY

    Malaria is the deadliest parasitic disease with 584.000 deaths in 2013 and 198 million estimated cases worldwide. While this number is decreasing each year, thanks to an expansion in malaria interventions and the use of artemisinin derivatives, drug-resistances are a major threat to the progresses made. In areas along the Cambodia–Thailand border, P. falciparum has become resistant to most available antimalarial medicines, and multi-drug resistance is a major concern.

    The current treatment policy is to use an Artemisinin-based Combination Therapy (ACT) which combines a fast acting drug—artemisinin derivative—with a long-lasting partner drug such as mefloquine, piperaquine, amodiaquine or lumefantrine. While partner drugs were supposed to limit the apparition of resistances, parasites resistant to both artemisinin and partner drug have emerged and spread in Cambodia.

    The objective of this study was to investigate about the in vitro efficacy of novel antimalarial drugs in the current context of multidrug resistance.